
Cheryl Rockman-Greenberg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4665728/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Asfotase Alfa Treatment Improves Survival for Perinatal and Infantile Hypophosphatasia. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 334-342.	1.8	189
2	Asfotase alfa therapy for children with hypophosphatasia. JCI Insight, 2016, 1, e85971.	2.3	123
3	Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia. Bone, 2019, 121, 149-162.	1.4	99
4	Diagnostic delay is common among patients with hypophosphatasia: initial findings from a longitudinal, prospective, global registry. BMC Musculoskeletal Disorders, 2019, 20, 80.	0.8	69
5	ldentifying Non–Duchenne Muscular Dystrophy–Positive and False Negative Results in Prior Duchenne Muscular Dystrophy Newborn Screening Programs. JAMA Neurology, 2016, 73, 111.	4.5	48
6	Efficacy and Safety of Asfotase Alfa in Infants and Young Children With Hypophosphatasia: A Phase 2 Open-Label Study. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2735-2747.	1.8	46
7	The health system impact of false positive newborn screening results for medium-chain acyl-CoA dehydrogenase deficiency: a cohort study. Orphanet Journal of Rare Diseases, 2016, 11, 12.	1.2	38
8	Burden of Illness in Adults With Hypophosphatasia: Data From the Global Hypophosphatasia Patient Registry. Journal of Bone and Mineral Research, 2020, 35, 2171-2178.	3.1	38
9	Hypophosphatasia. Pediatric Endocrinology Reviews, 2013, 10 Suppl 2, 380-8.	1.2	37
10	Caffeine is a risk factor for osteopenia of prematurity in preterm infants: a cohort study. BMC Pediatrics, 2018, 18, 9.	0.7	31
11	Cloacal exstrophy and related abdominal wall defects in Manitoba: Incidence and demographic factors. Clinical Genetics, 1985, 27, 241-251.	1.0	18
12	An insight into the mechanisms of COVID-19, SARS-CoV2 infection severity concerning β-cell survival and cardiovascular conditions in diabetic patients. Molecular and Cellular Biochemistry, 2022, 477, 1681-1695.	1.4	15
13	A novel CCBE1 mutation leading to a mild form of hennekam syndrome: case report and review of the literature. BMC Medical Genetics, 2015, 16, 28.	2.1	14
14	Enzyme replacement therapy in perinatal hypophosphatasia: Case report of a negative outcome and lessons for clinical practice. Molecular Genetics and Metabolism Reports, 2018, 14, 22-26.	0.4	14
15	Development of iPSC-based clinical trial selection platform for patients with ultrarare diseases. Science Advances, 2022, 8, eabl4370.	4.7	13
16	Multigenerational case examples of hypophosphatasia: Challenges in genetic counseling and disease management. Molecular Genetics and Metabolism Reports, 2020, 25, 100661.	0.4	12
17	Generation and Evaluation of Isogenic iPSC as a Source of Cell Replacement Therapies in Patients with Kearns Sayre Syndrome. Cells, 2021, 10, 568.	1.8	11
18	Health services use among children diagnosed with medium-chain acyl-CoA dehydrogenase deficiency through newborn screening: a cohort study in Ontario, Canada. Orphanet Journal of Rare Diseases, 2019, 14, 70.	1.2	9

#	Article	IF	CITATIONS
19	ALPL mutations in adults with rheumatologic disorders and low serum alkaline phosphatase activity. Journal of Bone and Mineral Metabolism, 2019, 37, 893-899.	1.3	9
20	Induced pluripotent stem cell line UOMi002-A from a patient with Leigh syndrome with compound heterozygous mutations in the NDUFV1 gene. Stem Cell Research, 2020, 48, 101964.	0.3	8
21	Dental outcomes for children receiving Strensiq $\hat{A}^{ extsf{@}}$ for Hypophosphatasia. Bone, 2021, 152, 116089.	1.4	8
22	Independent Registries Are Cost-Effective Tools to Provide Mandatory Postauthorization Surveillance for Orphan Medicinal Products. Value in Health, 2021, 24, 268-273.	0.1	7
23	Does specialist physician supply affect pediatric asthma health outcomes?. BMC Health Services Research, 2018, 18, 247.	0.9	6
24	Health Care for Mitochondrial Disorders in Canada: A Survey of Physicians. Canadian Journal of Neurological Sciences, 2019, 46, 717-726.	0.3	6
25	Newborn Screening for IKBKB Deficiency in Manitoba, Using Genetic Mutation Analysis. Journal of Clinical Immunology, 2018, 38, 742-744.	2.0	5
26	Generation of human induced pluripotent stem cell (hiPSC) line UOMi005-A from PBMCs of a patient with Kearns-Sayre syndrome. Stem Cell Research, 2021, 53, 102283.	0.3	5
27	Neonatal hypoglycemia and the CPT1A P479L variant in term newborns: A retrospective cohort study of Inuit newborns from Kivalliq Nunavut. Paediatrics and Child Health, 2021, 26, 218-227.	0.3	4
28	Association of the CPT1A p.P479L Metabolic Gene Variant With Childhood Respiratory and Other Infectious Illness in Nunavut. Frontiers in Pediatrics, 2021, 9, 678553.	0.9	4
29	Letter to the Editor: "Efficacy and Safety of Asfotase Alfa in Infants and Young Children With Hypophosphatasia: A Phase 2 Open-Label Study― Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3146-3147.	1.8	3
30	Generation of human induced pluripotent stem cell (hiPSC) line UOMi001-A from a patient with Leigh-like syndrome harbouring compound heterozygous variants in ECHS1 gene. Stem Cell Research, 2020, 48, 101934.	0.3	3
31	Therapeutic challenges in two adolescent male patients with Fabry disease and high antibody titres. Molecular Genetics and Metabolism Reports, 2020, 24, 100618.	0.4	2
32	Type A Aortic Dissection, Apparent Mineralocorticoid Excess Syndrome, and Syndromic Aortic Root Dilatation. AACE Clinical Case Reports, 2017, 3, 291-293.	0.4	1
33	Establishment of variant free-iPSC (UOMi003-A) line from patient with mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes. Stem Cell Research, 2020, 48, 101935.	0.3	0
34	Mass Spectrometry Evaluation of Biomarkers in the Vitreous Fluid in Gaucher Disease Type 3 with Disease Progression Despite Long-Term Treatment. Diagnostics, 2020, 10, 69.	1.3	0
35	Human induced pluripotent stem cell (hiPSC) line UOMi006-A derived from PBMCs of a patient with Kearns-Sayre syndrome. Stem Cell Research, 2021, 53, 102355.	0.3	0
36	Establishment of a new human iPSC cell line (UOMi007-A) from a patient with Hypophosphatasia. Stem Cell Research, 2022, 63, 102839.	0.3	0